DOCSLIB.ORG

Mouse Eaf2 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Eaf2 Conditional Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Eaf2 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Eaf2 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Eaf2 gene (NCBI Reference Sequence: NM_001113401 ; Ensembl: ENSMUSG00000022838 ) is located on Mouse chromosome 16. 6 exons are identified, with the ATG start codon in exon 1 and the TGA stop codon in exon 6 (Transcript: ENSMUST00000114829). Exon 4 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Eaf2 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP24-400K10 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a null allele exhibit premature death, enlarged heart and prostate associate with hypertrophy, and increased incidence of tumors. Exon 4 starts from about 43.13% of the coding region. The knockout of Exon 4 will result in frameshift of the gene. The size of intron 3 for 5'-loxP site insertion: 2311 bp, and the size of intron 4 for 3'-loxP site insertion: 7170 bp. The size of effective cKO region: ~646 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 4 6 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Eaf2 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(7146bp) | A(34.17% 2442) | C(17.35% 1240) | T(28.56% 2041) | G(19.91% 1423) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 3 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr16 - 36808411 36811410 3000 browser details YourSeq 107 1901 2045 3000 86.9% chr3 + 123687844 123687988 145 browser details YourSeq 96 1905 2134 3000 77.9% chr3 - 88067811 88068024 214 browser details YourSeq 94 1926 2176 3000 83.3% chr1 + 133682271 133682676 406 browser details YourSeq 93 1912 2141 3000 83.5% chr4 - 130187711 130188202 492 browser details YourSeq 93 1909 2110 3000 78.8% chr14 + 62938827 62939001 175 browser details YourSeq 91 1901 2099 3000 89.8% chr2 - 32670393 32670592 200 browser details YourSeq 91 1908 2040 3000 84.3% chr5 + 100216009 100216141 133 browser details YourSeq 90 1900 2043 3000 81.3% chr8 - 25493704 25493847 144 browser details YourSeq 90 1905 2040 3000 83.1% chr13 - 41613892 41614027 136 browser details YourSeq 90 1905 2039 3000 82.5% chrX + 101613874 101614002 129 browser details YourSeq 90 1901 2140 3000 74.9% chr3 + 82007856 82008037 182 browser details YourSeq 87 1917 2043 3000 84.3% chr19 - 7515009 7515135 127 browser details YourSeq 86 1910 2043 3000 82.1% chr9 + 40619469 40619602 134 browser details YourSeq 85 1922 2043 3000 82.5% chr15 - 100473145 100473264 120 browser details YourSeq 85 1900 2040 3000 89.8% chrX + 10508945 10509087 143 browser details YourSeq 85 1910 2042 3000 82.0% chr11 + 67403356 67403488 133 browser details YourSeq 83 1900 2038 3000 79.9% chr8 - 118370949 118371087 139 browser details YourSeq 83 1905 2029 3000 83.2% chr19 - 9925813 9925937 125 browser details YourSeq 82 1878 2014 3000 83.7% chr11 + 96589111 96589248 138 Note: The 3000 bp section upstream of Exon 4 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr16 - 36804765 36807764 3000 browser details YourSeq 171 2782 2963 3000 97.3% chr2 - 20817017 20817209 193 browser details YourSeq 170 2764 2958 3000 94.4% chr17 + 7137590 7137811 222 browser details YourSeq 169 2782 2961 3000 97.3% chr18 - 36393382 36393934 553 browser details YourSeq 169 2778 2962 3000 96.2% chr17 + 6226698 6226884 187 browser details YourSeq 166 2774 2964 3000 93.4% chr7 + 130448420 130448607 188 browser details YourSeq 163 2778 2994 3000 95.1% chr14 + 54326183 54326419 237 browser details YourSeq 162 2751 2936 3000 92.1% chr4 - 129411750 129411928 179 browser details YourSeq 162 2778 2962 3000 95.0% chr1 - 153494358 153494553 196 browser details YourSeq 162 2779 2955 3000 96.1% chr8 + 61640454 61640650 197 browser details YourSeq 162 2778 2945 3000 98.3% chr11 + 75664949 75665116 168 browser details YourSeq 161 2767 2945 3000 93.6% chr12 - 44271606 44271777 172 browser details YourSeq 161 2779 2951 3000 95.4% chr9 + 13527005 13527176 172 browser details YourSeq 160 2768 2942 3000 97.1% chr18 + 35368506 35368684 179 browser details YourSeq 159 2779 2948 3000 97.1% chrX - 41461665 41461847 183 browser details YourSeq 159 2778 2945 3000 97.7% chr4 - 32071338 32071506 169 browser details YourSeq 159 2782 2950 3000 95.9% chr1 - 51504532 51504699 168 browser details YourSeq 159 2778 2945 3000 97.7% chr4 + 88741228 88741397 170 browser details YourSeq 159 2777 2945 3000 97.1% chr16 + 5054727 5054895 169 browser details YourSeq 158 2782 2949 3000 97.1% chr2 - 31070372 31070539 168 Note: The 3000 bp section downstream of Exon 4 is BLAT searched against the genome. No significant similarity is found. Page 4 of 8 https://www.alphaknockout.com Gene and protein information: Eaf2 ELL associated factor 2 [ Mus musculus (house mouse) ] Gene ID: 106389, updated on 24-Oct-2019 Gene summary Official Symbol Eaf2 provided by MGI Official Full Name ELL associated factor 2 provided by MGI Primary source MGI:MGI:2146616 See related Ensembl:ENSMUSG00000022838 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as U19; Festa; Traits; FESTA-L; FESTA-S; AW048865 Expression Broad expression in bladder adult (RPKM 1.1), kidney adult (RPKM 1.0) and 24 other tissues See more Orthologs human all Genomic context Location: 16; 16 B3 See Eaf2 in Genome Data Viewer Exon count: 8 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 16 NC_000082.6 (36792884..36875068, complement) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 16 NC_000082.5 (36792970..36874912, complement) Chromosome 16 - NC_000082.6 Page 5 of 8 https://www.alphaknockout.com Transcript information: This gene has 9 transcripts Gene: Eaf2 ENSMUSG00000022838 Description ELL associated factor 2 [Source:MGI Symbol;Acc:MGI:2146616] Gene Synonyms FESTA-L, FESTA-S, Festa, Traits, U19 Location Chromosome 16: 36,792,884-36,875,003 reverse strand. GRCm38:CM001009.2 About this gene This gene has 9 transcripts (splice variants), 198 orthologues, 1 paralogue, is a member of 1 Ensembl protein family and is associated with 12 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Eaf2-202 ENSMUST00000075946.11 1878 132aa ENSMUSP00000075331.5 Protein coding CCDS37335 Q91ZD6 TSL:1 GENCODE basic Eaf2-203 ENSMUST00000114825.2 1530 132aa ENSMUSP00000110473.1 Protein coding CCDS37335 Q91ZD6 TSL:1 GENCODE basic Eaf2-204 ENSMUST00000114829.8 1030 262aa ENSMUSP00000110477.2 Protein coding CCDS49843 Q91ZD6 TSL:1 GENCODE basic APPRIS P2 Eaf2-201 ENSMUST00000023537.5 849 195aa ENSMUSP00000023537.5 Protein coding - K4DI60 TSL:5 GENCODE basic APPRIS ALT2 Eaf2-205 ENSMUST00000134556.1 2377 No protein - Retained intron - - TSL:1 Eaf2-208 ENSMUST00000157072.7 1106 No protein - lncRNA - - TSL:5 Eaf2-206 ENSMUST00000138660.7 963 No protein - lncRNA - - TSL:1 Eaf2-209 ENSMUST00000231782.1 668 No protein - lncRNA - - - Eaf2-207 ENSMUST00000147053.1 667 No protein - lncRNA - - TSL:3 Page 6 of 8 https://www.alphaknockout.com 102.12 kb Forward strand 36.80Mb 36.82Mb 36.84Mb 36.86Mb 36.88Mb Genes Gm22617-201 >miRNA Iqcb1-206 >lncRNA Iqcb1-204 >retained intron 2600002D14Rik-201 >lncRNA (Comprehensive set... Iqcb1-202 >protein coding Golgb1-205 >lncRNA Iqcb1-201 >protein coding Iqcb1-208 >lncRNA Iqcb1-203 >lncRNA Golgb1-201 >protein coding Iqcb1-205 >lncRNA Golgb1-203 >protein coding Iqcb1-207 >lncRNA Golgb1-204 >protein coding Gm49599-201 >TEC Contigs AC117662.13 > AC154232.1 > Genes (Comprehensive set... < Slc15a2-201protein coding < Eaf2-205retained intron < Slc15a2-208protein coding < 4930565N06Rik-201lncRNA < Slc15a2-207nonsense mediated decay < Slc15a2-205protein coding < Slc15a2-212protein coding < Eaf2-203protein coding < Eaf2-202protein coding < Eaf2-208lncRNA < Eaf2-204protein coding < Eaf2-206lncRNA < Eaf2-209lncRNA < Eaf2-201protein
Load more

Recommended publications
  • Screening and Analysis of Pathogenic Genes During DMBA- Induced Buccal Mucosa Carcinogenesis in Golden Hamsters
    1619-1624.qxd 23/4/2010 09:56 Ì ™ÂÏ›‰·1619 ONCOLOGY REPORTS 23: 1619-1624, 2010 Screening and analysis of pathogenic genes during DMBA- induced buccal mucosa carcinogenesis in golden hamsters KAI YANG1, GUODONG ZHANG1, JIE MEI1, DAN CHEN1 and MINGJUN WU2 1Department of Oral and Maxillofacial Surgery, the First Affiliated Hospital, Chongqing Medical University, Chongqing; 2Institute of Life Sciences of Chongqing Medical University, Chongqing 400016, P.R. China Received December 18, 2009; Accepted February 9, 2010 DOI: 10.3892/or_00000803 Abstract. We designed to screen pathogenic genes related to Introduction the occurrence and development of oral buccal mucosa cancer by whole genome microarray and analyze the mechanisms There are 274,000 new cases of oral cancer in the world every of carcinogenesis. The golden hamster model of buccal year (1). Squamous cell carcinoma accounts for 90% of mucosa cancer was established by induction with DMBA. oral cancer, and buccal carcinoma is one of the most common cRNAs labeled with Cy3 were synthesized and hybridized oral cancers (2). Although the treatment of oral cancers has with Agilent Whole Rat Genome Arrays containing 41,000 markedly improved in recent decades, the 5-year survival genes/ESTs. A Venn diagram analysis was performed to rate for buccal carcinoma and other oral cancers is only 55- screen the continuously abnormally expressed genes. Our 60% (2-4). Therefore, it is of great significance to explore results show 5,255 significantly differentially expressed the molecular mechanisms of the occurrence and develop- genes in golden hamster pouch mucosa during the ment of oral mucosa carcinomas and search for effective progression of normal buccal mucosa to squamous cell therapeutic targets.
    [Show full text]
  • A Chromosome Level Genome of Astyanax Mexicanus Surface Fish for Comparing Population
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.189654; this version posted July 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Title 2 A chromosome level genome of Astyanax mexicanus surface fish for comparing population- 3 specific genetic differences contributing to trait evolution. 4 5 Authors 6 Wesley C. Warren1, Tyler E. Boggs2, Richard Borowsky3, Brian M. Carlson4, Estephany 7 Ferrufino5, Joshua B. Gross2, LaDeana Hillier6, Zhilian Hu7, Alex C. Keene8, Alexander Kenzior9, 8 Johanna E. Kowalko5, Chad Tomlinson10, Milinn Kremitzki10, Madeleine E. Lemieux11, Tina 9 Graves-Lindsay10, Suzanne E. McGaugh12, Jeff T. Miller12, Mathilda Mommersteeg7, Rachel L. 10 Moran12, Robert Peuß9, Edward Rice1, Misty R. Riddle13, Itzel Sifuentes-Romero5, Bethany A. 11 Stanhope5,8, Clifford J. Tabin13, Sunishka Thakur5, Yamamoto Yoshiyuki14, Nicolas Rohner9,15 12 13 Authors for correspondence: Wesley C. Warren ([email protected]), Nicolas Rohner 14 ([email protected]) 15 16 Affiliation 17 1Department of Animal Sciences, Department of Surgery, Institute for Data Science and 18 Informatics, University of Missouri, Bond Life Sciences Center, Columbia, MO 19 2 Department of Biological Sciences, University of Cincinnati, Cincinnati, OH 20 3 Department of Biology, New York University, New York, NY 21 4 Department of Biology, The College of Wooster, Wooster, OH 22 5 Harriet L. Wilkes Honors College, Florida Atlantic University, Jupiter FL 23 6 Department of Genome Sciences, University of Washington, Seattle, WA 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.189654; this version posted July 6, 2020.
    [Show full text]
  • PCR Analysis of Androgen-Regulated Genes in Human Lncap Prostate Cancer Cells
    Oncogene (2009) 28, 2051–2063 & 2009 Macmillan Publishers Limited All rights reserved 0950-9232/09 $32.00 www.nature.com/onc ONCOGENOMICS Microarray coupled to quantitative RT–PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells S Ngan, EA Stronach, A Photiou, J Waxman, S Ali and L Buluwela Department of Oncology, Imperial College London, London, UK The androgen receptor (AR) mediates the growth- 2006). The importance of AR in male development is stimulatory effects of androgens in prostate cancer cells. shown by the androgen insensitivity syndromes char- Identification of androgen-regulated genes in prostate acterized by mutations in the AR gene (Gottlieb et al., cancer cells is therefore of considerable importance for 2004). The prostate is a prototypical androgen-depen- defining the mechanisms of prostate-cancer development dent organ (Cunha et al., 1987; Davies and Eaton, 1991) and progression. Although several studies have used and prostate cancer, which has become the most microarrays to identify AR-regulated genes in prostate commonly diagnosed cancer in males in the western cancer cell lines and in prostate tumours, we present here world and is the second leading cause of male cancer the results of gene expression microarray profiling of the death, is androgen-dependent for its growth (Carter and androgen-responsive LNCaP prostate-cancer cell line Coffey, 1990; McConnell, 1991). Therefore, treatment is treated withR1881 for theidentification of androgen- directed at inhibiting prostate cancer growth by regulated genes. We show that the expression of 319 genes suppressing the action of the endogenous androgen or is stimulated by 24 hafter R1881 addition, witha similar its production.
    [Show full text]
  • Genomic Signature of Parity in the Breast of Premenopausal Women
    Santucci-Pereira et al. Breast Cancer Research (2019) 21:46 https://doi.org/10.1186/s13058-019-1128-x RESEARCH ARTICLE Open Access Genomic signature of parity in the breast of premenopausal women Julia Santucci-Pereira1*† , Anne Zeleniuch-Jacquotte2,3†, Yelena Afanasyeva2†, Hua Zhong2†, Michael Slifker4, Suraj Peri4, Eric A. Ross4, Ricardo López de Cicco1, Yubo Zhai1, Theresa Nguyen1, Fathima Sheriff1, Irma H. Russo1, Yanrong Su1, Alan A. Arslan2,5, Pal Bordas6,7, Per Lenner7, Janet Åhman6, Anna Stina Landström Eriksson6, Robert Johansson8, Göran Hallmans9, Paolo Toniolo5 and Jose Russo1 Abstract Background: Full-term pregnancy (FTP) at an early age confers long-term protection against breast cancer. Previously, we reported that a FTP imprints a specific gene expression profile in the breast of postmenopausal women. Herein, we evaluated gene expression changes induced by parity in the breast of premenopausal women. Methods: Gene expression profiling of normal breast tissue from 30 nulliparous (NP) and 79 parous (P) premenopausal volunteers was performed using Affymetrix microarrays. In addition to a discovery/validation analysis, we conducted an analysis of gene expression differences in P vs. NP women as a function of time since last FTP. Finally, a laser capture microdissection substudy was performed to compare the gene expression profile in the whole breast biopsy with that in the epithelial and stromal tissues. Results: Discovery/validation analysis identified 43 differentially expressed genes in P vs. NP breast. Analysis of expression as a function of time since FTP revealed 286 differentially expressed genes (238 up- and 48 downregulated) comparing all P vs. all NP, and/or P women whose last FTP was less than 5 years before biopsy vs.
    [Show full text]
  • ELL Antibody (C-Term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap9479b
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 ELL Antibody (C-term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP9479b Specification ELL Antibody (C-term) - Product Information Application WB,E Primary Accession P55199 Reactivity Human, Mouse Host Rabbit Clonality Polyclonal Isotype Rabbit Ig Calculated MW 68265 Antigen Region 516-545 ELL Antibody (C-term) - Additional Information Gene ID 8178 Western blot analysis of ELL Antibody Other Names (C-term) (Cat. #AP9479b) in mouse testis RNA polymerase II elongation factor ELL, tissue lysates (35ug/lane). ELL (arrow) was Eleven-nineteen lysine-rich leukemia detected using the purified Pab. protein, ELL, C19orf17 Target/Specificity ELL Antibody (C-term) - Background This ELL antibody is generated from rabbits immunized with a KLH conjugated synthetic Elongation factor that can increase the peptide between 516-545 amino acids from catalytic rate of RNA polymerase II the C-terminal region of human ELL. transcription by suppressing transient pausing Dilution by the polymerase at multiple sites along the WB~~1:1000 DNA. Format ELL Antibody (C-term) - References Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This ?Zhou, J., et al. J. Biol. Chem. antibody is purified through a protein A 284(28):19142-19152(2009) column, followed by peptide affinity ?Jiang, F., et al. Cancer Lett. purification. 253(2):265-272(2007) ?Matsuoka, S., et al. Science Storage 316(5828):1160-1166(2007) Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
    [Show full text]
  • Chromatin Accessibility Analysis Uncovers Regulatory Element Landscape in Prostate Cancer Progression Joonas Uusi-Mäkelä1,2*
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.08.287268; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Chromatin accessibility analysis uncovers regulatory element landscape in prostate cancer progression Joonas Uusi-Mäkelä1,2*, Ebrahim Afyounian1,2*, Francesco Tabaro1,2*, Tomi Hakkinen1,2*, Alessandro Lussana1,2, Anastasia Shcherban1,2, Matti Annala1,2, Riikka Nurminen1,2, Kati Kivinummi1,2, Teuvo L.J. Tammela1,2,3, Alfonso Urbanucci4, Leena Latonen5, Juha Kesseli1,2, Kirsi J. Granberg1,2, Tapio Visakorpi1,2,6, Matti Nykter1,2✦ 1 Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland 2 Tays Cancer Center, Tampere University Hospital, Tampere, Finland 3 Department of Urology, Tampere University Hospital, Tampere, Finland 4 Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway 5 Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland 6 Fimlab Laboratories Ltd, Tampere, Finland *These authors contributed equally. ✦Corresponding author 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.08.287268; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Aberrant oncogene functions and structural variation alter the chromatin structure in cancer cells.
    [Show full text]
  • Coexpression Networks Based on Natural Variation in Human Gene Expression at Baseline and Under Stress
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Fall 2010 Coexpression Networks Based on Natural Variation in Human Gene Expression at Baseline and Under Stress Renuka Nayak University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Computational Biology Commons, and the Genomics Commons Recommended Citation Nayak, Renuka, "Coexpression Networks Based on Natural Variation in Human Gene Expression at Baseline and Under Stress" (2010). Publicly Accessible Penn Dissertations. 1559. https://repository.upenn.edu/edissertations/1559 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1559 For more information, please contact [email protected]. Coexpression Networks Based on Natural Variation in Human Gene Expression at Baseline and Under Stress Abstract Genes interact in networks to orchestrate cellular processes. Here, we used coexpression networks based on natural variation in gene expression to study the functions and interactions of human genes. We asked how these networks change in response to stress. First, we studied human coexpression networks at baseline. We constructed networks by identifying correlations in expression levels of 8.9 million gene pairs in immortalized B cells from 295 individuals comprising three independent samples. The resulting networks allowed us to infer interactions between biological processes. We used the network to predict the functions of poorly-characterized human genes, and provided some experimental support. Examining genes implicated in disease, we found that IFIH1, a diabetes susceptibility gene, interacts with YES1, which affects glucose transport. Genes predisposing to the same diseases are clustered non-randomly in the network, suggesting that the network may be used to identify candidate genes that influence disease susceptibility.
    [Show full text]
  • Expression and Gene Regulation Network of EAF2 in Cervical Cancer Based on Data Mining
    Expression and gene regulation network of EAF2 in cervical cancer based on data mining Wei na Kong Xinjiang Medical University Aliated First Hospital Fan Guo Xinjiang Medical University Aliated First Hospital Yang chun Feng Xinjiang Medical University Aliated Tumor Hospital Jie Lv Xinjiang Medical University Aliated First Hospital Jia hui Fan Xinjiang Medical University Aliated First Hospital Yue Wang Xinjiang Medical University Aliated First Hospital Gang Zhao Xinjiang Medical University Aliated Traditional Chinese Medicine Hospital Hui li Wu Xinjiang Medical University Aliated Tumor Hospital Le Ai Xinjiang Medical University Aliated Tumor Hospital Xiu min Ma ( [email protected] ) https://orcid.org/0000-0001-8011-7513 Primary research Keywords: EAF2, cervical cancer, patient survival, clinical outcomes, cancer progression, multiomics analysis Posted Date: June 15th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-35101/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/21 Abstract Background: ELL-associated factor 2 (EAF2) plays an important role in transcription elongation and the regulation of gene expression in both mammalian cells as well as in lower eukaryotes concurrent . EAF2’s depletion has been demonstrated to enhance cell proliferation and greatly increase the risk of cancer. However, little is known about the expression and function of EAF2 in cervical cancer (CC) progression. Here, we comprehensively analyzed the expression of EAF2 and its clinical outcome in CC using publicly available cancer gene expression and patient survival data through various databases. Methods: We examined the differences of EAF2 expression between cancers and their normal tissues using the Oncomine, Gene expression Proling Interactive Analysis 2 (GEPIA2), the Gene Expression across Normal and Tumor tissue 2 (GENT2) database and UALCAN databases.
    [Show full text]
  • Conditional Deletion of ELL2 Induces Murine Prostate Intraepithelial Neoplasia
    235 2 L E PASCAL, K Z MASOODI, J LIU Prostate neoplasia in 235:2 123–136 Research and others ELL2-knockout mouse Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia Laura E Pascal1,*, Khalid Z Masoodi1,2,*, June Liu1,*,†, Xiaonan Qiu1,3, Qiong Song1,4, Yujuan Wang1, Yachen Zang1,5, Tiejun Yang1,6, Yao Wang1,7, Lora H Rigatti8, Uma Chandran9, Leandro M Colli10, Ricardo Z N Vencio11, Yi Lu12,13, Jian Zhang12,13 and Zhou Wang1,14,15 1Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA 2Transcriptomics Lab, Division of Plant Biotechnology, Sher-e-Kashmir University of Agricultural Sciences and Technology of Kashmir, Shalimar, Srinagar, Jammu and Kashmir, India 3School of Medicine, Tsinghua University, Beijing, China 4Center for Translational Medicine, Guangxi Medical University, Nanning, Guangxi, China 5Department of Urology, The Second Affiliated Hospital of Soochow University, Suzhou, China 6Department of Urology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China 7Department of Urology, China-Japan Hospital of Jilin University, Changchun, Jilin, China 8Division of Laboratory Animal Resources, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA 9Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA 10Ribeirao Preto Medical School, University of São Paulo, Ribeirão Preto-SP, Brazil 11Department of Computing and Mathematics FFCLRP-USP, University of São Paulo, Ribeirão
    [Show full text]
  • Text Mining Applied to Molecular Biology
    Text mining applied to molecular biology Rob Jelier The financial contributions of the WikiProfessional Initiative, the BAZIS foundation and SUWO, the Urological Research Foundation, for the publication of this thesis is gratefully acknowledged. Jelier R. Text-mining applied to molecular biology. PhD Thesis Erasmus University Rotterdam | with summary in Dutch. Cover design by the author, inspired by the work of Tord Boontje and Piet Mondriaan. ISBN: 978-90-8559-335-5 This thesis was typeset by the author with LATEX 2". c R. Jelier, 2007 Text mining applied to molecular biology Text mining toegepast voor de moleculaire biologie Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof. dr. S.W.J. Lamberts en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op donderdag 10 januari 2008 om 16.00 uur door Rob Jelier geboren te Dirksland Promotiecommissie Promotor Prof. dr. J. van der Lei Copromotoren Dr. ir. J.A. Kors Dr. ir. G.W. Jenster Overige leden Prof. dr. C.M. van Duijn Prof. dr. G.J.B. van Ommen Prof. dr. P.J. van der Spek The studies described in this thesis were performed when the author was a member of the Biosemantics group, department of Medical Informatics, Erasmus MC, the Netherlands. Acknowledgments Over the past few years I've frequently been asked, in one way or another: \Why do you forgo the spoils of capitalism for a mostly solitary life behind a computer?". Well, because science is fun. I feel it's a privilege to have the freedom to not constrain my curiosity, to play around a bit, to see how far I can push myself.
    [Show full text]
  • 1 Supplementary Material Figure S1. Volcano Plot of Differentially
    Supplementary material Figure S1. Volcano Plot of differentially expressed genes between preterm infants fed own mother’s milk (OMM) or pasteurized donated human milk (DHM). Table S1. The 10 most representative biological processes filtered for enrichment p- value in preterm infants. Biological Processes p-value Quantity of DEG* Transcription, DNA-templated 3.62x10-24 189 Regulation of transcription, DNA-templated 5.34x10-22 188 Transport 3.75x10-17 140 Cell cycle 1.03x10-13 65 Gene expression 3.38x10-10 60 Multicellular organismal development 6.97x10-10 86 1 Protein transport 1.73x10-09 56 Cell division 2.75x10-09 39 Blood coagulation 3.38x10-09 46 DNA repair 8.34x10-09 39 Table S2. Differential genes in transcriptomic analysis of exfoliated epithelial intestinal cells between preterm infants fed own mother’s milk (OMM) and pasteurized donated human milk (DHM). Gene name Gene Symbol p-value Fold-Change (OMM vs. DHM) (OMM vs. DHM) Lactalbumin, alpha LALBA 0.0024 2.92 Casein kappa CSN3 0.0024 2.59 Casein beta CSN2 0.0093 2.13 Cytochrome c oxidase subunit I COX1 0.0263 2.07 Casein alpha s1 CSN1S1 0.0084 1.71 Espin ESPN 0.0008 1.58 MTND2 ND2 0.0138 1.57 Small ubiquitin-like modifier 3 SUMO3 0.0037 1.54 Eukaryotic translation elongation EEF1A1 0.0365 1.53 factor 1 alpha 1 Ribosomal protein L10 RPL10 0.0195 1.52 Keratin associated protein 2-4 KRTAP2-4 0.0019 1.46 Serine peptidase inhibitor, Kunitz SPINT1 0.0007 1.44 type 1 Zinc finger family member 788 ZNF788 0.0000 1.43 Mitochondrial ribosomal protein MRPL38 0.0020 1.41 L38 Diacylglycerol
    [Show full text]
  • Analysis of Breast Cancer Subtypes by AP-ISA Biclustering Liying Yang1*, Yunyan Shen1, Xiguo Yuan1, Junying Zhang1 and Jianhua Wei2*
    Yang et al. BMC Bioinformatics (2017) 18:481 DOI 10.1186/s12859-017-1926-z RESEARCHARTICLE Open Access Analysis of breast cancer subtypes by AP-ISA biclustering Liying Yang1*, Yunyan Shen1, Xiguo Yuan1, Junying Zhang1 and Jianhua Wei2* Abstract Background: Gene expression profiling has led to the definition of breast cancer molecular subtypes: Basal-like, HER2-enriched, LuminalA, LuminalB and Normal-like. Different subtypes exhibit diverse responses to treatment. In the past years, several traditional clustering algorithms have been applied to analyze gene expression profiling. However, accurate identification of breast cancer subtypes, especially within highly variable LuminalA subtype, remains a challenge. Furthermore, the relationship between DNA methylation and expression level in different breast cancer subtypes is not clear. Results: In this study, a modified ISA biclustering algorithm, termed AP-ISA, was proposed to identify breast cancer subtypes. Comparing with ISA, AP-ISA provides the optimized strategy to select seeds and thresholds in the circumstance that prior knowledge is absent. Experimental results on 574 breast cancer samples were evaluated using clinical ER/PR information, PAM50 subtypes and the results of five peer to peer methods. One remarkable point in the experiment is that, AP-ISA divided the expression profiles of the luminal samples into four distinct classes. Enrichment analysis and methylation analysis showed obvious distinction among the four subgroups. Tumor variability within the Luminal subtype is observed in the experiments, which could contribute to the development of novel directed therapies. Conclusions: Aiming at breast cancer subtype classification, a novel biclustering algorithm AP-ISA is proposed in this paper. AP-ISA classifies breast cancer into seven subtypes and we argue that there are four subtypes in luminal samples.
    [Show full text]